BCAX Bicara Therapeutics Inc.
$22.81▼ -1.26%
Healthcare
Other
After hours
$22.81▲ +0.00%
Sep 11, 7:30 PM ET
Volume 450.4K
Avg Volume (10D) 489.2K
Key Metrics & Fundamentals
Market Cap
$1.51B
P/E Ratio
–
Div Yield
–%
52W Range
10.30 - 30.99
% vs 50 MA
-12.29%
% vs 200 MA
7.84%
RSI-14
39.3
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.00
Free Cash Flow
-$44.27M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$59.91M
COGS
–
Operating Exp
$59.95M
Operating Income
-$59.95M
EBIT
-$59.95M
Pretax Income
-$55.38M
Net Income
-$55.44M
EPS (Diluted)
-0.82
Price & Volume History
Loading chart…
Recent News
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 3, 2026 12:30 PM
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
Insider Monkey · Aug 19, 2026 1:56 PM
BMO Capital Initiates Bicara Therapeutics at Outperform
MT Newswires · Aug 19, 2026 10:10 AM
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 18, 2026 3:13 PM
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 14, 2026 12:30 PM
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX)
Simply Wall St. · Aug 13, 2026 10:10 AM
Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing
MT Newswires · Aug 12, 2026 8:31 PM
Bicara Therapeutics Insider Sold Shares Worth $279,750, According to a Recent SEC Filing
MT Newswires · Aug 12, 2026 8:31 PM
Bicara Therapeutics Insider Sold Shares Worth $349,591, According to a Recent SEC Filing
MT Newswires · Aug 12, 2026 8:30 PM
Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says
MT Newswires · Aug 11, 2026 5:28 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See BCAX's money flow as a full page
Social Sentiment
No Reddit posts found for BCAX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.